Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Return on Equity (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Return on Equity for 8 consecutive years, with 2.9% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Equity fell 268.0% year-over-year to 2.9%, compared with a TTM value of 2.9% through Sep 2025, down 268.0%, and an annual FY2024 reading of 1.02%, up 59.0% over the prior year.
  • Return on Equity was 2.9% for Q3 2025 at X4 Pharmaceuticals, up from 7.58% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.65% in Q1 2025 and bottomed at 7.58% in Q2 2025.
  • Average Return on Equity over 5 years is 1.78%, with a median of 1.53% recorded in 2023.
  • Peak annual rise in Return on Equity hit 559bps in 2025, while the deepest fall reached -795bps in 2025.
  • Year by year, Return on Equity stood at 1.33% in 2021, then dropped by -4bps to 1.38% in 2022, then fell by -23bps to 1.7% in 2023, then surged by 46bps to 0.92% in 2024, then plummeted by -217bps to 2.9% in 2025.
  • Business Quant data shows Return on Equity for XFOR at 2.9% in Q3 2025, 7.58% in Q2 2025, and 0.65% in Q1 2025.